If you are experiencing problems downloading PDF or HTML fulltext, our helpdesk recommend clearing your browser cache and trying again. If you need help in clearing your cache, please click here . Still need help? Email email@example.com
Controlled studies of cromolyn treatment of asthmatic children have revealed benefits beyond the incredible safety of the drug. It is now recognized that the patient with asthma will have decreased asthma and less bronchial hyperreactivity when treated for more than two months with cromolyn. Also, the reduced sensitivity of beta-receptors with chronic use of beta adrenergic drugs is abated with concomitant cromolyn use. It is hoped that the studies with nedocromil will reveal additional benefits with this class of antiasthmatic medication.
Allergy and Asthma Proceedings is a peer reviewed publication dedicated to distributing timely scientific research regarding advancements in the knowledge and practice of allergy, asthma and immunology. Its primary readership consists of allergists and pulmonologists.
The goal of the Proceedings is to publish articles with a predominantly clinical focus which directly impact quality of care for patients with allergic disease and asthma.
Featured topics include asthma, rhinitis, sinusitis, food allergies, allergic skin diseases, diagnostic techniques, allergens, and treatment modalities. Published material includes peer-reviewed original research, clinical trials and review articles.
Articles marked "F" offer free full text for personal noncommercial use only.